Latest Comments

Is Teva doomed after Copaxone’s increased competition and Laquinimod’s failed Phase III trial?

Is Teva doomed after Copaxone’s increased competition and Laquinimod’s failed Phase III trial?

Highlights from the 2017 ATS Conference

Highlights from the 2017 ATS Conference

Artificial intelligence: the beginning of a new era in healthcare?

Artificial intelligence: the beginning of a new era in healthcare?

Pipeline biosimilar surge in emerging markets

Pipeline biosimilar surge in emerging markets

How your gut microbiome can interfere with cancer treatment and how to avoid it

How your gut microbiome can interfere with cancer treatment and how to avoid it

Can DAA treatment increase the risk of HCC? Emerging data points towards ‘no’

Can DAA treatment increase the risk of HCC? Emerging data points towards ‘no’

Highlights from the 2017 ATS Conference: positive results for AstraZeneca’s Daliresp beyond reducing the risk of exacerbations

Highlights from the 2017 ATS Conference: positive results for AstraZeneca’s Daliresp beyond reducing the risk of exacerbations

Eiger Bio’s PAH drug Ubenimex moves one step closer to fulfilling an unmet need

Eiger Bio’s PAH drug Ubenimex moves one step closer to fulfilling an unmet need

Seikagaku inks deal with Ono Pharmaceutical, strengthening its position in the Osteoarthritis market

Seikagaku inks deal with Ono Pharmaceutical, strengthening its position in the Osteoarthritis market

Baxalta’s patent case on Hemophilia A candidate Emicizumab could make Roche bleed

Baxalta’s patent case on Hemophilia A candidate Emicizumab could make Roche bleed

Pacific Biosciences: don’t count them out yet

Pacific Biosciences: don’t count them out yet

Radicava: first new treatment for ALS approved by FDA after two decades

Radicava: first new treatment for ALS approved by FDA after two decades

Gilead and AbbVie look to fill remaining gaps in Hepatitis C treatment

Gilead and AbbVie look to fill remaining gaps in Hepatitis C treatment

Lundbeck and Otsuka's brexipiprazole shows positive but confusing results

Lundbeck and Otsuka's brexipiprazole shows positive but confusing results

FMT National Registry Will Help Elucidate Best Practices for Recurrent C. difficile Infections

FMT National Registry Will Help Elucidate Best Practices for Recurrent C. difficile Infections

Hepatitis C Therapy – A Light at the End of the Tunnel?

Hepatitis C Therapy – A Light at the End of the Tunnel?

China, US, and Brazil Face Rise in HIV-HCV Co-infection

China, US, and Brazil Face Rise in HIV-HCV Co-infection

FDA’s acceptance of Santen’s Opsiria marks a milestone for the company

FDA’s acceptance of Santen’s Opsiria marks a milestone for the company

Novartis boosts ophthalmology pipeline by in-licensing clinical-stage dry eye therapy

Novartis boosts ophthalmology pipeline by in-licensing clinical-stage dry eye therapy

The likely relocation of the EMA is bad news for the pharmaceutical industry and the health of 500 million Europeans

The likely relocation of the EMA is bad news for the pharmaceutical industry and the health of 500 million Europeans

Researchers raise hope for affordable malaria diagnostics

Researchers raise hope for affordable malaria diagnostics